IDSA published updated Lyme disease guidelines in 2020 (Clinical Infectious Diseases, 72(1): e1–e48). The key change from 2006: the 2020 guidelines formally acknowledge Post-Treatment Lyme Disease Syndrome (PTLDS) as a clinical entity, distinguish between three subtypes, and note that a subset of patients — those with Type 1 (persistent infection) — may benefit from extended antibiotic treatment under specialist supervision. The 2006 guidelines did not acknowledge PTLDS as a distinct entity. They recommended short-course antibiotics and stated that there was no evidence for extended treatment. That was the state of the evidence in 2006. It is not the state of the evidence in 2025. An insurer who cites 2006 guidelines to deny 2020-standard treatment is not applying the current clinical consensus. They are applying a 20-year-old snapshot of knowledge that their own industry's medical advisory body has updated and superseded. PEMCLAU V12 has the evidence delta: the exact differences between the 2006 and 2020 guidelines, cross-referenced against the claims being denied. The delta is documented. The denial is deliberate.

The Canada Health Act (RSC 1985, c. C-6, s. 7) requires provincial health insurance programs to cover all medically necessary insured services. Extended antibiotic treatment for PTLDS Type 1, now supported by the 2020 IDSA guidelines and implemented by specialists in infectious disease, qualifies as medically necessary treatment for a recognized clinical condition. Insurer denial of this treatment, where the patient has a specialist recommendation in hand, engages the Act. The Ontario Human Rights Code (s. 1) prohibits discrimination in services on the basis of disability. Lyme disease and PTLDS are recognized disabilities. Denying evidence-based treatment for a disability using superseded clinical guidelines is discriminatory on its face. The test is whether the denial is connected to the disability — it manifestly is. Stewart v. Lloyd's Underwriters (2022 BCCA 84) established in British Columbia that an insurer has a duty to adjudicate coverage claims in good faith and must apply current, not outdated, medical evidence to coverage decisions. The BC Court of Appeal's reasoning applies with equal force in Ontario: an insurer who knows the guidelines have been updated and continues to cite the superseded version is not adjudicating in good faith.

The strategic architecture here is two simultaneous tracks. This is the Thurgood Marshall approach: not just the individual case, but the case that changes the policy for everyone. Track 1 — HRTO (Human Rights Tribunal of Ontario): The HRTO has jurisdiction to order a policy change. A successful HRTO application in a Lyme coverage denial case can result in an order requiring the insurer to revise its coverage criteria for all Ontario Lyme patients. The limitation period is one year from the last act of discrimination — meaning the most recent denial letter. The individual damages in HRTO are capped, but the policy change order is not. Every denied claim from 2006 forward reopens when the insurer's coverage criteria are revised. Track 2 — ONSC (Ontario Superior Court, civil): Full damages action including punitive damages for bad faith denial. Two-year limitation period. Punitive damages in insurance bad faith cases in Ontario can be substantial — Whiten v. Pilot Insurance Co. [2002] 1 SCR 595 awarded $1 million in punitive damages for insurance bad faith. That case involved a house fire claim. This involves a patient's health and years of their life. The insurer cannot win both tracks simultaneously. A policy change order from the HRTO changes the substantive basis for the ONSC action. Winning the HRTO first means every class member's claim is automatically strengthened in the civil track.

Marshall's insight from Brown v. Board of Education was not just the win in the case. It was the doctrine that made the win inevitable. The NAACP's legal strategy was to build a series of cases that each established a piece of the principle, so that by the time the big case came, the court was already most of the way there. This strategy does the same. Each individual HRTO application establishes the factual record: insurer cited 2006 guidelines, 2020 guidelines supersede them, patient was denied treatment that the current evidence supports, patient has a recognized disability. When enough individual applications create that record — five, ten, twenty — the class application writes itself. The HRTO issues a policy change order. The insurer revises its coverage criteria. Every Ontario Lyme patient who was denied coverage under the old criteria now has a reopened claim. This is the flywheel: one successful HRTO application generates the precedent that reopens every denied claim that looks like it. The class action is not the goal. The policy change is. The class action is what happens automatically when the policy change comes too late for the people it already hurt.

Individual HRTO damages: general damages for injury to dignity, feelings, and self-respect (typically $15,000–$50,000 in Ontario human rights cases) plus out-of-pocket treatment costs incurred because coverage was denied, plus income loss attributable to treatment delay. ONSC civil damages add the full income loss calculation (Blenus v. Fraser method) plus punitive damages for bad faith. Representative rain cheque: Patient denied coverage for extended antibiotic treatment recommended by specialist. Paid out-of-pocket: $18,000 over 18 months. Income loss during untreated period: $67,000. HRTO general damages: $35,000. Punitive (ONSC): $200,000–$1,000,000. Total range: $320,000–$1,100,000 per plaintiff. Pool status: Current 0 of 30. HRTO limitation period is running on every denial letter issued in the past 12 months. Intake opens now. Every patient who received a denial letter citing IDSA 2006 within the past year is within time.